---
title: "Kesimpta (ofatumumab) in relapsing multiple sclerosis: Specific populations questions"
description: "Specific populations questions on Kesimpta (ofatumumab) in relapsing multiple sclerosis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding and Pediatric use. Questions: What do animal studies show about Kesimpta and fertility? Can Kesimpta be used during pregnancy? Is there a Kesimpta pregnancy registry? How long should birth control be used after stopping Kesimpta? 4 further questions follow. 8 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/specific-populations"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Kesimpta (ofatumumab) in relapsing multiple sclerosis: Specific populations questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kesimpta](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)

## Specific populations

<a id="kesimpta-fertility"></a>

### What do animal studies show about Kesimpta and fertility?

> “No effects on reproductive parameters, including hormones, menstrual cycle, sperm analysis, or histopathological 
> evaluation of reproductive organs, were observed in male or female monkeys administered ofatumumab for 13 weeks by 
> intravenous injection (5 weekly doses of 0, 10, and 100 mg/kg, followed by biweekly doses of 0, 3, and 20 mg/kg). 
> Plasma exposures (Cavg) at the high dose tested in monkeys are greater than 500 times that in humans at the recommended 
> human maintenance dose of 20 mg/month.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

<a id="kesimpta-geriatric-use"></a>

### Was Kesimpta studied in older adults (geriatric use)?

> “Clinical studies of KESIMPTA did not include sufficient numbers of geriatric patients to determine whether they respond 
> differently from younger subjects.”

Source: [KESIMPTA: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=8)

<a id="kesimpta-kidney-liver-impairment"></a>

### Has Kesimpta been studied in kidney or liver impairment?

> “Pharmacokinetics of ofatumumab in patients with renal or hepatic impairment have not been studied.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

> “Ofatumumab, a monoclonal antibody, is not likely to undergo renal excretion.”

Source: [KESIMPTA: Prescribing information, page 10, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=10)

## Pregnancy and breastfeeding

<a id="kesimpta-pregnancy"></a>

### Can Kesimpta be used during pregnancy?

> “There are no adequate data on the developmental risk associated with the use of KESIMPTA in pregnant women. KESIMPTA may cross the placenta and cause fetal B-cell depletion based on findings from animal studies. Advise patients of reproductive potential to use effective contraception while receiving KESIMPTA and for at least 6 months after the last dose.<sup>1</sup>”

Source: [KESIMPTA: FAQs, captured 2026-11-13](https://www.kesimptahcp.com/resources/faqs#:~:text=There%20are%20no%20adequate%20data,6%20months%20after%20the%20last)

On the page, select: Can patients take KESIMPTA while pregnant?

> “Based on animal data, KESIMPTA can cause fetal harm due to B-cell lymphopenia and reduce antibody response in 
> offspring exposed to KESIMPTA in utero. Transient peripheral B-cell depletion and lymphocytopenia have been reported 
> in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. Advise pregnant 
> women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception while 
> receiving KESIMPTA and for at least 6 months after the last dose [see Use in Specific Populations (8.1)].”

Source: [KESIMPTA: Prescribing information, page 5, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=5)

<a id="kesimpta-pregnancy-registry"></a>

### Is there a Kesimpta pregnancy registry?

> “There is a registry for women who become pregnant during treatment with KESIMPTA. If a patient becomes pregnant while taking KESIMPTA, advise them to contact MotherToBaby by calling 1-877-311-8972, by sending an email to MotherToBaby@health.ucsd.edu, or go to https://mothertobaby.org/ongoing-study/kesimpta-ofatumumab/.”

Source: [KESIMPTA: FAQs, captured 2026-11-13](https://www.kesimptahcp.com/resources/faqs#:~:text=There%20is%20a%20registry%20for,MotherToBaby%40health.ucsd.edu%2C%20or%20go%20to%20https%3A%2F%2Fmothertobaby.org%2Fongoing%2Dstudy%2Fkesimpta%2Dofatumumab%2F.)

On the page, select: Can patients take KESIMPTA while pregnant?

> “There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to KESIMPTA during 
> pregnancy. Healthcare providers are encouraged to enroll pregnant patients, or pregnant women may register themselves 
> in the MotherToBaby Pregnancy Study in Multiple Sclerosis by calling 1-877-311-8972, by sending an email to 
> MotherToBaby@health.ucsd.edu, or by going to www.mothertobaby.org/join-study.”

Source: [KESIMPTA: Prescribing information, page 7, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=7)

<a id="kesimpta-contraception"></a>

### How long should birth control be used after stopping Kesimpta?

> “Females of childbearing potential should use effective contraception while receiving KESIMPTA and for 6 months after 
> the last treatment of KESIMPTA.”

Source: [KESIMPTA: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=8)

<a id="kesimpta-breastfeeding"></a>

### Can patients take Kesimpta while breastfeeding?

> “There are no data on the presence of KESIMPTA in human milk, the effects on the breastfed infant, or the effects of the drug on milk production. Human IgG is excreted in human milk, and the potential for absorption of KESIMPTA to lead to B-cell depletion in the infant is unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for KESIMPTA and any potential adverse effects on the breastfed infant from KESIMPTA or from the underlying maternal condition.<sup>1</sup>”

Source: [KESIMPTA: FAQs, captured 2026-11-13](https://www.kesimptahcp.com/resources/faqs#:~:text=There%20are%20no%20data%20on,or%20from%20the%20underlying%20maternal)

On the page, select: Can patients take KESIMPTA while breastfeeding?

## Pediatric use

<a id="kesimpta-pediatric-use"></a>

### Is Kesimpta safe and effective for children?

> “Safety and effectiveness in pediatric patients have not been established.”

Source: [KESIMPTA: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf#page=8)

## Related pages
- [Medical information: Kesimpta (ofatumumab): Relapsing multiple sclerosis](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis)
- [Indication](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/kesimpta--relapsing-multiple-sclerosis/access-and-coverage)
